S2 Genomics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
S2 Genomics was a Livermore, California life science tools company founded in 2016, a leader in tissue sample preparation for single-cell genomics assays. Its benchtop Singulator platform used single-use cartridges to enable reproducible, rapid and automated tissue dissociation into single-cell or nuclei suspensions, advancing research in neuroscience and oncology. The platform comprised a benchtop instrument, consumables and over 80 validated protocols, and was adopted by academic, pharma and biotech customers.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
S2 Genomics is founded in Livermore, California to build laboratory automation for processing solid tissues for single-cell applications.
- Series A
S2 Genomics raises $16 million in Series A funding from BroadOak Capital Partners and Research Corporation Technologies to accelerate commercial adoption of the Singulator platform.
- Acquisition
On September 17, 2025, Precision Cell Systems (PCS) announces its official launch following the strategic acquisitions of S2 Genomics and ORFLO, consolidating best-in-class technologies serving over 700 customers for cell analysis.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.